SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Iovance Biotherapeutics, Inc. engages in the development and commercialization of cell therapies using autologous tumor-infiltrating lymphocytes (TIL) for the treatment of cancer. Its products include Amtagvi (lifileucel), and Proleukin (aldesleukin). The firm also develops investigational TIL therapies for other solid tumor cancers. The company was founded by Robert T. Brooke on September 17, 2007 and is headquartered in San Carlos, CA.

Iovance Biotherapeutics Inc

Iovances announcement of positive Phase 2 lifileucel results in previously treated metastatic non-small cell lung cancer, alongside a precision-medicine update, is driving attention and a sharp after-hours move. Traders are largely enthusiastic about the therapys potential beyond melanoma, while some question how strong the detailed results and regulatory path will be and warn of a possible sell-the-news reaction.

Alphabet, Inc. is a holding company, which engages in software, health care, transportation, and other technologies. It operates through the following segments: Google Services, Google Cloud, and Other Bets. The Google Services segment includes products and services, such as ads, Android, Chrome, devices, Google Maps, Google Play, Search, and YouTube. The Google Cloud segment refers to infrastructure and platform services, collaboration tools, and other services for enterprise customers. The Other Bets segment relates to the sale of healthcare-related services and internet services. The company was founded by Lawrence E. Page and Sergey Mikhaylovich Brin on October 2, 2015 and is headquartered in Mountain View, CA.

Alphabet Inc - Ordinary Shares - Class A

Alphabet Inc Class A

Alphabets quarterly results triggered a sharp selloff, with traders focused on the earnings miss, slower Search and advertising growth, negative free cash flow, and plans for substantially higher AI infrastructure spending. The debate is whether strong Cloud and AI growth will justify that investment: dip buyers call the decline an overreaction, while bears question Search monetization and the returns on rising capex.

Marvell Technology, Inc. engages in the design, development, and sale of integrated circuits. Its products include data processing units, security solutions, automotive, coherent DSP, DCI optical modules, ethernet controllers, ethernet PHYs, ethernet switches, linear driver, PAM DSP, transimpedance amplifiers, fibre channel, HDD, SSD controller, storage accelerators, ASIC, and Marvell government solutions. It operates through the following geographical segments: United States, Singapore, Israel, India, China, and Others. The company was founded by Wei Li Dai and Pantas Sutardja in 1995 and is headquartered in Wilmington, DE.

Marvell Technology Inc

Reports that Marvell is in advanced talks to acquire Lumentum have drawn attention, though no deal is final. Traders are divided between viewing the combination as a strategic way to strengthen Marvells AI-data-center optics position and worrying about financing, debt, and potential shareholder dilution.

Alphabet Inc - Ordinary Shares - Class C

Alphabets earnings miss, heavy AI infrastructure spending and concerns about weaker Search and advertising growth are driving the discussion, despite strong Cloud growth. Traders are split between viewing the selloff as an overreaction and worrying that AI spending and pressure on Search monetization will weigh on cash flow and returns.

ServiceNow, Inc. engages in the provision of an end-to-end workflow automation platform for digital businesses. Its Now Platform is a cloud-based solution embedded with artificial intelligence (AI) and machine learning (ML). The company was founded by Frederic B. Luddy in June 2004 and is headquartered in Santa Clara, CA.

ServiceNow Inc

ServiceNows mixed Q3 results are driving attention: an adjusted-earnings miss and a softer Q4 contracted-revenue growth outlook overshadowed revenue growth and a higher AI contract target, renewing concerns about deceleration and whether AI can support its valuation. Traders are split between viewing the selloff as justified given high expectations and treating it as an overreaction to otherwise solid growth.

Lumentum Holdings, Inc. engages in the provision of optical and photonic products. It operates through the Cloud and Networking, and Industrial Tech segments. The Cloud and Networking segment refers to a portfolio of optical and photonic components, modules, and subsystems. The Industrial Tech segment includes solid-state lasers, kilowatt-class fiber lasers, ultrafast lasers, diode lasers, and gas lasers. The company was founded in 1979 and is headquartered in San Jose, CA.

Lumentum Holdings Inc

Lumentum is drawing attention after reports that Marvell is in advanced talks to acquire it, a potential deal that could give Marvell access to scarce optical components for AI data centers. Traders see strategic value for Lumentum but debate the rumors credibility, price and financing, with no agreement confirmed and sharp price swings fueling caution.

SELLAS Life Sciences Group, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of immunotherapeutic for cancer indications. Its product pipeline includes galinpepimut-S. The company was founded by Angelos M. Stergiou on April 3, 2006 and is headquartered in New York, NY.

SELLAS Life Sciences Group Inc

Sellass Phase 3 REGAL trial reached its 80th event, triggering final analysis and bringing preliminary topline results closer; the announcement did not disclose whether GPS improved survival. The sharp selloff prompted divided reactions: some traders saw the long trial timeline as encouraging and bought the dip, while others stressed that efficacy remains unconfirmed ahead of a high-stakes readout.

Fortinet, Inc. provides cybersecurity solutions to a variety of businesses, such as enterprises, communication service providers, government organizations, and small to medium-sized businesses. Its product portfolio includes network security, secure access service edge, enterprise networking, security operations, application security, and operational technology. The company was founded by Ken Xie and Michael Xie in November 2000 and is headquartered in Sunnyvale, CA.

Fortinet Inc

Fortinets Q3 earnings reaction is the dominant topic: despite headline earnings and revenue beats and higher full-year revenue guidance, traders cite slowing product growth, softer billings momentum, margin pressure, and a reduced service-revenue outlook. Bulls call the selloff excessive given the results, while bears argue that growth and business mix disappointed lofty expectations; the weakness is also weighing on other cybersecurity stocks.

GE Vernova, Inc. engages in the electric power industry. It operates through the following segments: Power, Wind, and Electrification. The Power segment offers design, manufacture, and servicing gas, nuclear, hydro, and steam technologies, providing a critical foundation of dispatchable, flexible, stable, and reliable power. The Wind segment manages wind generation technologies, including onshore and offshore wind turbines and blades. The Electrification segment refers to the grid solutions, power conversion, electrification software, and solar and storage solutions technologies required for the transmission, distribution, conversion, storage, and orchestration of electricity from point of generation to point of consumption. The company was founded November 9, 2021 and is headquartered in Cambridge, MA.

GE Vernova Inc.

GE Vernovas quarterly results beat expectations and its 2026 outlook improved, while the proposed Trench Group acquisition has prompted questions about its cost and funding. Traders are split between viewing the post-results decline as an overreaction given strong orders and power-demand prospects, and worrying that the acquisition and valuation temper the upbeat results.

Amazon.com, Inc. is a multinational technology company, which engages in the provision of online retail shopping services. It operates through the following segments: North America, International, and Amazon Web Services (AWS). The North America segment offers retail sale of consumer products, including from sellers, advertising, and subscriptions services through North America-focused online and physical stores. The International segment focuses on retail sale of consumer products, including sellers, advertising, and subscription services through internationally focused online stores. The AWS segment is composed of global sales of computers, storage, databases, and other services for start-ups, enterprises, government agencies, and academic institutions. The company was founded by Jeffrey P. Bezos in July 1994 and is headquartered in Seattle, WA.

Amazon.com Inc.

Amazon.com Inc

Amazons quarterly earnings are the dominant focus, with traders watching AWS growth and margins alongside capital-spending plans and whether AI demand can translate into returns. Bulls point to strong cloud demand, while skeptics fear heavy investment and cash-flow pressure could weigh on the stock even if results are strong.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

$IOVA they said positive meaning that Orr will be over 20% and let’s see the durability (I’m expecting a “not reach yet” based on what Fred mentioned)…but guys, the last sentence…is it something to find the tumor easlily for them? Like a chemical mark? What do they mean with it?

Elliot

BioSwings™

Bert Igermann

Tom Jackson

John Morin

StockTwits for iOS

 they said positive meaning that Orr will be over 20% and let’s see the durability (I’m expecting a “not reach yet” based on what Fred mentioned)…but guys, the last sentence…is it something to find the tumor easlily for them? Like a chemical mark? What do they mean with it?

Giuseppe

@Gius_me yeah that durability read is the good part imo on $IOVA. not reached yet means responders are still holding, not that it faded. and that last line is not a chemical tag imo, its the precision angle, figuring out which tumor reactive clones actually drive the response so they can pick patients better. the 8:30am ET call today is where that detail lands, and the runup into that kind of date is where I lay out my full plan at https://bioswings.com

Biotech catalyst trade alerts on Telegram. FDA decisions, trial readouts and AdComs, with entry, stop, targets and exit timing on every alert. 3 days free, no card.

Bioswings

BioSwings | Get positioned before the FDA decides

StockTwits Web

 yeah that durability read is the good part imo on 

. not reached yet means responders are still holding, not that it faded. and that last line is not a chemical tag imo, its the precision angle, figuring out which tumor reactive clones actually drive the response so they can pick patients better. the 8:30am ET call today is where that detail lands, and the runup into that kind of date is where I lay out my full plan at 

@BiotechSwings thank youuuu!!! So it’s like breaking down different tumors and focus on them…I hope fda won’t require a new trial focus only on that kind of tumors

 thank youuuu!!! So it’s like breaking down different tumors and focus on them…I hope fda won’t require a new trial focus only on that kind of tumors

@Gius_me there have been multiple guesses tonight. Personally, I think they may have identified a reproducible biomarker that either improves responses or tells them if lifileucel will induce a response. Some think it has to do with a CNPV.

 there have been multiple guesses tonight. Personally, I think they may have identified a reproducible biomarker that either improves responses or tells them if lifileucel will induce a response. Some think it has to do with a CNPV.

@Gius_me yeah that is the read imo on $IOVA. precision here is about matching the right tumor types to the therapy, not starting from scratch. if the data holds in those groups the hope is the path forward builds on what they already ran, not a whole new trial

. precision here is about matching the right tumor types to the therapy, not starting from scratch. if the data holds in those groups the hope is the path forward builds on what they already ran, not a whole new trial